Sensei Biotherapeutics, INC Form 4 insider transactions

Faeth Therapeutics, Inc. reports that Chief Financial Officer Brian C. Stephenson acquired a significant number of company shares across multiple transactions in late June and early July 2026.

Faeth Therapeutics, Inc. Chief Financial Officer, Brian C. Stephenson, reported the purchase of common stock on June 24th and June 26th, 2026.

Faeth Therapeutics, Inc. reports that Chief Financial Officer Brian C. Stephenson acquired a significant number of company shares across multiple transactions on June 22nd and 23rd, 2026.

Faeth Therapeutics, Inc. reports that President and CEO Anand Kiran Parikh acquired common stock through option exercises and purchases.

Director Saira Ramasastry was granted 25,000 stock options in Sensei Biotherapeutics, Inc. as part of a standard equity compensation plan.

CEO Anand Kiran Parikh converted Series B Preferred Stock into 761,428 shares of common stock following a merger.

Director Stephen M. Hahn reported transactions involving Sensei Biotherapeutics, Inc. common stock and Series B Preferred Stock, alongside stock options.

Anand Kiran Parikh, President and CEO of Sensei Biotherapeutics, Inc., has filed an amendment to a Form 4 detailing transactions related to a merger and stock options.

Sensei Biotherapeutics President and PEO Christopher Gerry was granted 220,000 stock options following shareholder approval of the 2026 Equity Incentive Plan.

Director Phillip B. Donenberg was granted 12,500 stock options in Sensei Biotherapeutics, Inc. as part of his compensation.

Director Bob Holmen was granted 12,500 stock options in Sensei Biotherapeutics, Inc. as part of his compensation package.

Cambrian BioPharma Inc. reported the sale of 25,000 shares of Sensei Biotherapeutics, Inc. common stock on June 1, 2026.

Reporting person James Peyer sold 25,000 shares of Sensei Biotherapeutics common stock on June 1, 2026.

Millennium Management LLC reported multiple purchases and sales of Sensei Biotherapeutics common stock in late March 2026, increasing its overall beneficial ownership and proactively disgorging potential short-swing profits.

Josiah Craver, PFO & PAO of Sensei Biotherapeutics, Inc., received a stock option grant for 80,000 shares.

Phillip B. Donenberg, a Director at Sensei Biotherapeutics, Inc., was granted 23,100 stock options as a supplemental grant to align with the company's compensation policy.

Sensei Biotherapeutics' Chief Operating Officer, Anand Parikh, reported the acquisition of Series B Preferred Stock and employee stock options following the merger with Faeth Holdings Therapeutics.

Cambrian BioPharma Inc., a 10% owner of Sensei Biotherapeutics, Inc., reported multiple sales of common stock totaling 6,612 shares on December 9, 2025, alongside an option exercise, pursuant to a Rule 10b5-1 plan.

James Peyer, a Director and 10% owner of Sensei Biotherapeutics, reported multiple sales of common stock totaling 6,612 shares, alongside the exercise of 395 stock options.

Cambrian BioPharma Inc., a 10% owner and director of Sensei Biotherapeutics, Inc., reported multiple sales of common stock totaling 21,295 shares in early December 2025.

Sensei Biotherapeutics director James Peyer reported multiple sales of common stock totaling 21,295 shares in early December 2025.

Sensei Biotherapeutics, Inc. Director Thomas G. Ricks was granted 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Sensei Biotherapeutics, Inc. Director and 10% owner James Peyer reported the indirect acquisition of 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Sensei Biotherapeutics, Inc. Director Kristian Humer was granted 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Cambrian BioPharma Inc., a 10% owner and director of Sensei Biotherapeutics, Inc., was granted 19,000 stock options with an exercise price of $0.3202, vesting over one year.

Sensei Biotherapeutics, Inc. Director Bob Holmen was granted 19,000 stock options with an exercise price of $0.3202 per share, aligning his interests with shareholder value.

Sensei Biotherapeutics, Inc. Director William R. Ringo was granted 19,000 stock options with an exercise price of $0.3202, vesting over a one-year period.

John Celebi, CEO of Sensei Biotherapeutics, reports disposition of shares to cover tax obligations and accumulation of shares through the employee stock purchase plan.

Edward van der Horst, Chief Scientific Officer of Sensei Biotherapeutics, reports disposition of shares to cover tax obligations and holdings including shares purchased through the employee stock purchase plan.

Stephanie Krebs, Chief Business Officer of Sensei Biotherapeutics, received stock options for 120,000 shares on February 14, 2025.